Nam Nguyen, MD
Radiation Oncology · Washington, DCNPI 1538266234
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $764 of the $931 with a category attached, or 82.1%. 12 manufacturers reported payments, led by AstraZeneca at 26.4% of the total. Reporting peaked in 2022 at $288 and has fallen 76.7% since, to $67 in 2025.
Across 20 payments — averaging $46.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$246
- Jazz Pharmaceuticals Inc.$167
- Johnson & Johnson$127
- Blue Earth Diagnostics$121
- Tactile Systems Technology Inc$67
- Boehringer Ingelheim$51
- plus $152 from 6 others
What the payments were for
- Food & beverage$76482%
- Education$16718%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $246 |
| Jazz Pharmaceuticals Inc. | 2 | $167 |
| Johnson & Johnson(2 entities) | 2 | $127 |
| Blue Earth Diagnostics | 1 | $121 |
| Tactile Systems Technology Inc | 4 | $67 |
| Boehringer Ingelheim | 2 | $51 |
| Progenics Pharmaceuticals, Inc. | 1 | $44 |
| Reflexion Medical, Inc. | 1 | $37 |
| Myovant Sciences Inc. | 2 | $28 |
| Abbott | 1 | $18 |
| Bayer | 1 | $13 |
| Clovis Oncology, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$931 in reported general payments places this provider in the 55th percentile of 25 radiation oncology providers in District of Columbia.
See all radiation oncology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 15 | $493 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Washington
- Sean CollinsWashington$395K
- Jonathan LischalkWashington$55K
- Christina TsienWashington$53K
- Brian CollinsWashington$27K
- Keith UngerWashington$5K
- Rajanish SinglaWashington$5K
- Rachit KumarWashington$4K
- Martin Ojong-NtuiWashington$2K
- Jill RemickWashington$2K
- Matthew ForsthoefelWashington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.